RIGEL PHARMACEUTICALS, INC. Deferred Revenue
RIGEL PHARMACEUTICALS, INC. (RIGL) had Deferred Revenue of $3.76 million as of 2016-06-30, per its 10-Q filed 2016-08-02.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2017-03-07
- 2016-06-30: Deferred Revenue, Current $3.76M.
- 2016-03-31: Deferred Revenue, Current $8.59M.
- 2015-12-31: Deferred Revenue, Current $13.43M.
- 2015-09-30: Deferred Revenue, Current $18.26M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2016-06-30 | $3.76M 10-Q · filed 2016-08-02 |
| 2016-03-31 | $8.59M 10-Q · filed 2016-05-03 |
| 2015-12-31 | $13.43M 10-K · filed 2017-03-07 |
| 2015-09-30 | $18.26M 10-Q · filed 2015-11-03 |
| 2015-06-30 | $19.34M 10-Q · filed 2015-08-04 |
| 2015-03-31 | $19.34M 10-Q · filed 2015-05-07 |
| 2011-06-30 | $105.00K 10-Q · filed 2011-08-02 |
| 2010-12-31 | $0.00 10-Q · filed 2011-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |